Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
laiBIOTIC
- Development stage
- Unknown
- Lead developer
- LAINCO
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
laiBIOTIC is an oral probiotic food supplement developed and marketed by LAINCO. It is formulated with a combination of six beneficial live lactic ferment strains: Streptococcus thermophilus UAST-09, Lactobacillus acidophilus UALA-01, Lactiplantibacillus plantarum subsp. plantarum UALP-05, Lacticaseibacillus casei UALC-03, Lacticaseibacillus rhamnosus DSM 33560, and Bifidobacterium bifidum UABB-10. Each capsule contains 1.5 x 10⁹ CFU of each strain, totaling 9 x 10⁹ CFU per capsule. laiBIOTIC is indicated to help restore and maintain the balance of the intestinal microbiota, regulate intestinal transit, prevent antibiotic-associated diarrhea, improve lactose intolerance, and support the eradication of Helicobacter pylori.
- Brand names
- laiBIOTIC
Beyond the preview
Go deeper on laiBIOTIC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on laiBIOTIC.